Acknowledgements
The authors thank the patients and their families for their permission to include their information in DECIPHER. The authors would also like to thank all registered DECIPHER users for depositing and seeking consent to share patient data. The DECIPHER project was given a favourable NRES REC opinion by Cambridge South (previously Cambridgeshire 4 REC), REC reference 04/MRE05/50, in November 2004. DECIPHER submits annual progress reports to ensure this favourable opinion applies for the duration of the research. DECIPHER is supported by Wellcome funding, grant WT206194. Helen Firth is supported by The Wellcome award WT200990/Z/16/Z Designing, developing and delivering integrated foundations for genomic medicine. Fiona Cunnigham and Sarah E. Hunt receive funding from the Wellcome Trust (grant number WT108749/Z/15/Z) and the European Molecular Biology Laboratory. This research was funded in whole, or in part, by the Wellcome Trust [Grant numbers WT206194, WT200990/Z/16/Z, WT108749/Z/15/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. Matthew Hurles is a co-founder, shareholder and non-executive director of Congenica Ltd., a diagnostic software company. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.